BHVN:NYE-Biohaven Pharmaceutical Holding Company Ltd (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 134.01

Change

-0.57 (-0.42)%

Market Cap

USD 8.80B

Volume

0.20M

Avg Analyst Target

USD 113.08 (-15.62%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological diseases and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as id developing Rimegepant for preventive treatment of migraine and other non-migraine indications; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as respiratory complications and non-migraine studies; and BHV-3100 for non-migraine indications. The company also offers Troriluzole, which is in phase III clinical trials for spinocerebellar ataxia and obsessive compulsive disorders, as well as Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000/5500 that is in phase I clinical trial for neuropsychiatric indications; and Verdiperstat, a product that is in phase III trial for multiple system atrophy and amyotrophic lateral sclerosis. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was incorporated in 2013 and is headquartered in New Haven, Connecticut.

Company Website : http://www.biohavenpharma.com

Address : 215 Church Street, New Haven, CT, United States, 06510

Employees : 825

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.03

52 Week High : 139.66

Short Ratio : 7.48

52 Week Low : 60.20

Shorted Shares : 3,584,309

200 Day Moving Average : 97.40

Shorted Shares Previous Month : 4,319,710

50 Day Moving Average : 126.46

Shares Held By Insiders : 12.33%

Short Percentage : 5.00%

Shares Held by Institutions : 111.53%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

-0.90 (-0.88%)

 USD177.33B 34.78 3.79
RCUS Arcus Biosciences Inc

+0.03 (+0.08%)

 USD2.51B N/A N/A
ADCT ADC Therapeutics SA

+1.19 (+4.23%)

 USD2.21B -99,999.99 N/A
MYOV Myovant Sciences Ltd

+0.18 (+0.81%)

 USD2.03B N/A N/A
ZYME Zymeworks Inc

+0.25 (+0.81%)

 USD1.53B 300.20 N/A
RFL Rafael Holdings Inc

+0.53 (+1.48%)

 USD0.73B N/A N/A
AMAM Ambrx Biopharma Inc.

-0.91 (-6.10%)

 USD0.62B N/A N/A
BTX Brooklyn ImmunoTherapeutics In..

+0.09 (+0.93%)

 USD0.60B 2.32 N/A
CVM CEL-SCI Corporation

+0.10 (+0.85%)

 USD0.51B N/A N/A
PFNX Pfenex Inc

N/A

 USD0.44B 268.67 63.90

ETFs Containing BHVN

Symbol Name Weight Mer Price(Change) Market Cap
AGED:LSE iShares Ageing Population.. 0.00 % 0.40 %

+0.08 (+1.05%)

 USD0.98B
AGES:LSE iShares IV Public Limited.. 0.00 % 0.40 %

+4.75 (+0.84%)

 USD0.98B
DRDR:LSE iShares IV Public Limited.. 0.00 % 0.40 %

+0.38 (+0.05%)

 USD2.55B
HEAL:LSE iShares IV Public Limited.. 0.00 % 0.40 %

+0.03 (+0.29%)

 USD2.55B
BBSC J.P. Morgan Exchange-Trad.. 0.00 % 0.09 %

+0.98 (+1.52%)

 N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 56.35% 89% B+ 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.35% 89% B+ 92% A-
Trailing 12 Months  
Capital Gain 111.61% 85% B 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 111.61% 85% B 89% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 39.42% 64% D 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.42% 64% D 92% A-
Risk Return Profile  
Volatility (Standard Deviation) 39.03% 57% F 26% F
Risk Adjusted Return 101.02% 96% A 91% A-
Market Capitalization 8.80B 97% A+ 80% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 31.82 7% F 3% F
Price / Cash Flow Ratio -12.52 67% D+ 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -1,134.26% 10% F 0% N/A
Return on Assets -72.77% 10% F 0% N/A
Debt to Equity Ratio -68.20% 71% C- 96% A
Technical Ratios  
Short Ratio 7.48 30% F 11% F
Short Percent 6.36% 40% F 35% F
Beta 1.03 68% D+ 54% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector